Revenue growing, gross margins expanding from 7% to 15% in two quarters, cash operating burn down 95% year-over-year. The distribution business is a vehicle. The owned brands. Sky Premium Life nutraceuticals. Are the thesis. If the mix shift continues, this transitions from a low-margin distribution company to a branded consumer health company using its own logistics as the delivery channel.
Cosmos Health distributes pharmaceuticals in Greece and Cyprus and is layering owned nutraceutical brands on top of that distribution infrastructure. Q3 2025 revenue came in at $17.1M. 38 percent higher than Q3 2024. Q2 2025 was $14.75M, up 11.7 percent. The revenue is growing. But the more important number is the gross margin line: 15.21 percent in Q3 2025, up 549 basis points year-over-year. 7.89 percent in Q2 2025, up 208 basis points. 14.95 percent in Q1 2025, up 581 basis points. The margin is expanding every quarter, and the expansion is not coming from operational efficiency in the distribution business. It is coming from product mix; the owned brands carry dramatically higher margins than third-party pharmaceutical distribution.
The mechanism is the product mix shift. Pharmaceutical distribution margins top out in the low to mid single digits. Cosmos's own branded products; the Sky Premium Life nutraceutical line, carry gross margins the company targets at approximately 87 percent. Every dollar of revenue that shifts from third-party distribution toward owned brands is a dollar that carries dramatically higher margin. The margin expansion trend visible in the quarterly filings is the owned brand strategy working in real time. The question is not whether the strategy is theoretically sound; the question is how fast the mix shifts and whether the owned brands can scale to a level that structurally changes the margin profile of the entire company.
The Human Translation: The Pizza Slice Problem, Solved Version. Six months ago, Cosmos was making razor-thin margins delivering other people's products; acting as a middleman in the pharmaceutical supply chain. The trucks would go out full and come back empty, and the company kept four or five cents on every dollar. Now they are starting to put their own products on the same trucks. The trucks are the same. The routes are the same. The delivery infrastructure is the same. But the margins on what is inside the trucks are getting dramatically better. Instead of delivering someone else's products for a 5 percent margin, they are delivering their own vitamins and supplements for an 87 percent margin using the exact same logistics network. The business model is transitioning in real time and the transition is visible in the financial statements.
The friction is the capital structure. Cosmos has funded its growth through equity issuances and the share count has expanded materially. Cash operating burn dropped 95 percent year-over-year in Q1 2025; from $3.4M to $190K. Which suggests the business is approaching operational self-sufficiency. But the dilution already in the system means existing shareholders absorbed the cost of getting to this point. The per-share value of the margin improvement depends on the share count remaining stable from here. Additional dilution at this stage would dilute the very margin improvement that makes the thesis work.
Adjusted EBITDA turned positive at $0.37M in Q1 2025. 157 percent improvement from a $640K loss in Q1 2024. The H1 2025 gross profit grew 53 percent year-over-year. The direction is right. The pace of the owned brand mix shift determines how fast the margin story compounds. If Sky Premium Life revenue grows to represent 30 or 40 percent of total revenue in the next two years, the blended gross margin for the company approaches 30 percent or higher; a fundamentally different financial profile than the sub-10 percent margins of a distribution company.
The Sky Premium Life brand is the analytical centerpiece. The product line includes vitamins, dietary supplements, functional foods, and health-oriented consumer products. The brand is available through the company's own e-commerce channels, Amazon, and a growing network of retail pharmacy locations in Greece and Southern Europe. At an 87 percent target gross margin, every dollar of Sky Premium Life revenue contributes approximately 82 cents more to gross profit than a dollar of distribution revenue. That differential is the entire thesis. If the brand scales, the company transforms. If the brand stalls at a small fraction of total revenue, Cosmos remains a pharmaceutical distribution company with thin margins and limited upside.
The Greek and Southern European pharmaceutical distribution market provides a stable but low-growth foundation. Greece's pharmaceutical market is regulated, with drug pricing controlled by the government. Distribution margins are set by competitive dynamics and regulatory frameworks that do not allow significant margin expansion. This is why the distribution business alone does not generate excitement; it is a utility-like function with utility-like margins. The value of the distribution business is not the margin it generates but the infrastructure it provides: the warehousing, the logistics network, the pharmacy relationships, and the regulatory licenses that allow Cosmos to operate in the market. That infrastructure becomes enormously more valuable when it is used to deliver high-margin owned products instead of low-margin third-party pharmaceuticals.
Geographic expansion is part of the growth plan. Cosmos has been building distribution capabilities beyond Greece and Cyprus, with presence or partnerships in the United Kingdom, the United Arab Emirates, and Vietnam. International expansion of the Sky Premium Life brand is the high-upside scenario: the same brand sold through the same distribution model in new geographies. However, international expansion is expensive, requires local regulatory compliance, and adds complexity before it adds profit. The near-term focus should be on whether the existing Greek and Cypriot distribution infrastructure can be further leveraged for owned brand growth before the company stretches into new markets.
Management credibility is a relevant factor at this stage. CEO Grigorios Siokas has been executing the transition from pure distribution to owned brands over several years. The margin expansion visible in the 2025 quarterly filings is the first concrete financial evidence that the strategy is producing results at the income statement level. The execution has been slower than initial timelines suggested; which is common in business model transitions, but the direction is now confirmed by the data. Institutional investors evaluating Cosmos will weight the trajectory of the margin expansion more heavily than the absolute level, because the trajectory shows whether the mix shift is accelerating or plateauing.
The valuation context matters. Pharmaceutical distribution companies trade at revenue multiples that reflect their thin margins; typically 0.1x to 0.3x revenue. Branded consumer health companies with 30+ percent gross margins trade at meaningfully higher multiples; often 1x to 3x revenue or more. Cosmos currently trades somewhere in between, reflecting the market's uncertainty about whether the mix shift will be permanent and material. If the gross margin sustains above 15 percent for the next two quarters and continues expanding, the market may begin repricing the company from a distribution multiple to a branded consumer health multiple. That repricing is where the potential returns live. If the margin reverts toward single digits, the repricing does not happen and the thesis is slower than expected.
The operational infrastructure that Cosmos has built in Greece and Southern Europe; warehousing, cold chain logistics, pharmacy relationships, regulatory licenses, and distribution routes; represents years of accumulated investment that would be extremely difficult and expensive for a new entrant to replicate. This infrastructure was built to serve the pharmaceutical distribution business, but its value multiplies when the same trucks, warehouses, and pharmacy relationships are used to distribute high-margin owned products. The incremental cost of adding Sky Premium Life products to an existing distribution route is near zero; the truck is already making the delivery. The pharmacy already has a commercial relationship with Cosmos. The regulatory license already covers nutraceutical products. This infrastructure leverage is why the gross margin expands as the owned brand mix increases: the delivery cost is already being incurred for the distribution business, so every Sky Premium Life unit added to the delivery is essentially pure incremental margin above the product cost.
Dossiers, weekly roundup editions, and podcast notes. Free. No paywall. Unsubscribe anytime.